In September 2025, FDA's Center for Tobacco Products launched a pilot program to streamline how it reviews premarket tobacco product applications (PMTAs) for nicotine pouches. A persistent claim in the trade press is that FDA later scrapped the program. That is not what happened, and suppliers who planned around a cancellation planned around the wrong thing.
What FDA actually did was narrower and, for anyone with a pending application, more useful. On May 7, 2026, CTP Acting Director Bret Koplow wrote that "No additional products will be added to the nicotine pouch pilot. Instead, because the pilot has realized significant success in accelerating review of nicotine pouch PMTAs, CTP intends to incorporate lessons learned from the pilot into the review for all nicotine pouch PMTAs."
The pilot was closed to new entrants. It was not shut down, and the applications already inside it kept moving. On August 4, 2026, FDA authorized four more on! nicotine pouch products from Helix Innovations LLC (Rich Berry 2 mg, Cappuccino 2 mg, Cappuccino 4 mg, and Autumn Spice 2 mg) explicitly through the pilot, and described the program in the present tense as having "streamlined the FDA's review processes, which has led to faster resolution of issues, decreased time needed for applicants to respond to deficiency letters, and more efficient scientific reviews."
That is the opposite of a program being written off. It is a program being generalized.
What the Pilot Actually Changed, and What It Never Changed
It matters to be precise here, because the widely repeated version of this story gets the mechanism wrong.
According to FDA's own launch announcement, the pilot's changes were to the review process, not to the evidentiary standard. FDA said its "case-by-case review of individual applications will increase efficiency by focusing review on the most critical elements for this product category," and that the pilot would "feature increased real-time communication between FDA and applicants with the goal of providing more frequent feedback and shorter review timeframes." FDA intended "to have ongoing conversations with applicants to discuss missing information or request clarification with the hope to address issues sooner or at least limit the number and severity of issues included in a deficiency letter."
Read that list again. Every item is about communication cadence and review sequencing. None of it is a documentation waiver.
FDA never announced that pilot applicants could substitute category-wide literature for product-specific evidence, and it never published a relaxed ingredient documentation standard. The controlling legal test did not move: a product must still be shown to be "appropriate for the protection of the public health" (APPH) under Section 910(c)(2) of the Federal Food, Drug, and Cosmetic Act, with submissions governed by 21 CFR Part 1114. Suppliers who were told the pilot lowered the ingredient bar were told something FDA never said.
This distinction has a practical edge. If the pilot had been a documentation holiday, its closure to new products would have raised the bar back up, and there would be a real "before and after" for your customers' evidence packages. Because the pilot was a process improvement, closing it to new entrants changes almost nothing about what your customers must document. What changed is that FDA now intends to apply the faster process to everyone.
The Results the Pilot Produced
The pilot's track record is the reason FDA is generalizing it rather than retiring it.
The first decisions came in December 2025, when FDA authorized six on! PLUS nicotine pouch products (Mint, Tobacco, and Wintergreen, each at 6 mg and 9 mg). FDA completed scientific review in what it called "record time," and in the May 2026 statement quantified it: authorizations issued "just three months after launching scientific review, a record time for the FDA's evaluation of a PMTA."
Set that against the pathway's historical pace. ZYN's 20 nicotine pouch products were authorized on January 16, 2025, the first time FDA had ever authorized a nicotine pouch, after what the agency described as "an extensive scientific review." Three months versus a review measured in years is not a rounding difference.
FDA also reported broader throughput gains in the same May 2026 statement: CTP "reduced the backlog of applications by approximately 70 percent" in 2025, and "[t]here is no longer a queue for applications pending Acceptance Review," so a PMTA now "will, upon receipt, almost immediately enter the first phase of application review."
As of August 19, 2026, FDA's authorized nicotine pouch list contained 32 products across two manufacturers. Every other nicotine pouch on the US market is there without marketing authorization.
What This Means for Planning: Faster Is Not Easier
The temptation is to read "faster reviews" as "lower burden." It is closer to the reverse.
FDA's own explanation of why the pilot worked points at applicant readiness. In the May 2026 statement, FDA noted that "[i]n several cases, FDA requested additional information via real-time communication with the applicant while the application was undergoing scientific review," and that "[t]his process has given the applicants an earlier start for compiling additional information for submission to the FDA that had been omitted from the PMTA but is needed to complete scientific review." FDA also acknowledged the limit: "Thorough submissions and rigorous review still take time. In some cases, the applicant is working with FDA to respond to questions and agency requests for information and the agency is awaiting information from the applicant."
That is a compressed feedback loop, and a compressed loop rewards whoever can answer fastest. When FDA calls mid-review asking for constituent-level detail on an ingredient, the manufacturer who can forward a batch-specific Certificate of Analysis that afternoon keeps their timeline. The manufacturer who has to open a request with an offshore supplier and wait three weeks does not. Under the old cadence, that delay hid inside a multi-year queue. Under the new one, it is the critical path.
What This Means for Your Nicotine Ingredient Documentation
Every ingredient in a PMTA must be documented to FDA's satisfaction. For nicotine, the primary active ingredient, that package typically includes the following.
Purity and grade specifications. USP/EP grade nicotine is the practical documentation standard in PMTA ingredient submissions. The Certificate of Analysis should carry grade certification, assay percentage, and a full impurity profile, at batch level for traceability. FDA's February 2026 roundtable materials on product characterization list the recurring gaps directly: CoAs "missing: target specification with units, quantitative acceptance criteria with units, test data average, either standard deviation or minimum and maximum values." Those slides carry FDA's disclaimer that they are not a formal dissemination of Agency policy, but as a description of what reviewers keep finding wrong, they are hard to improve on.
HPHC characterization. The nicotine ingredient's contribution to the finished product's Harmful and Potentially Harmful Constituent profile must be documentable, including Tobacco Specific Nitrosamines (TSNAs) and any carbonyls relevant to the product format. FDA's evaluations of the authorized pouches turned substantially on this: the agency found the newly authorized on! products "contain lower levels of most HPHCs when compared to other oral and smokeless tobacco products, many of which were too low to be quantified."
Stability data. The application must show that ingredient specifications hold through the product's shelf life. FDA's roundtable materials recommend measurements at the beginning, middle, and end of the proposed shelf life.
Nicotine identity and source detail. FDA's product characterization materials ask for nicotine form (for example, salt), nicotine form name (for example, nicotine lactate), nicotine source (tobacco-derived or non-tobacco), enantiomeric purity for non-tobacco nicotine, purity or grade, and a target quantity and range for each ingredient with units. Nicotine salts formulated for pouch delivery differ meaningfully by salt form, and that detail belongs in the record rather than in a phone call.
Manufacturing quality documentation. Documentation of GMP status and audit history for the manufacturing partner supports the manufacturer's ability to demonstrate consistent ingredient quality across production batches.
Tobacco Product Master Files (TPMFs). A TPMF is a confidential FDA submission holding a supplier's proprietary ingredient and composition data. Manufacturers cross-reference a TPMF in their PMTA, satisfying ingredient documentation requirements without forcing the supplier to disclose trade secrets to the applicant or the public. A supplier with a current, comprehensive TPMF cuts manufacturer documentation burden materially. A supplier without one leaves the manufacturer to document ingredient details independently, typically with less precision and no confidentiality protection for the supplier's formulations.
Why US-Sourced Nicotine Changes the Compliance Calculation
Supply chain documentation is a structural component of the PMTA, so the sourcing decision has regulatory consequences and not just procurement ones.
A US-based supply chain with a certified manufacturing partner simplifies the documentation trail concretely. Import documentation complexity drops. Response time to FDA requests shortens. Manufacturing partner audits are accessible on shorter notice. In a review model built on real-time back-and-forth, the ability to respond quickly with verifiable documentation is not a nicety.
The contrast with unverified offshore sourcing is consequential. Traceability from raw material origin through final delivery is part of the PMTA's ingredient documentation expectations. Building that traceability retroactively, during an active review, while FDA waits, is a material liability.
For a full breakdown of how nicotine sourcing decisions interact with PMTA submission requirements, see PMTA Requirements: How Your Nicotine Source Affects FDA Submissions.
Five Questions to Ask Your Nicotine Supplier Right Now
- Do you have an active Tobacco Product Master File (TPMF) on file with FDA, and can you grant us right of reference for our PMTA?
- What grade certifications (USP/EP) are included in your CoA, and does each lot carry target specifications with units, quantitative acceptance criteria, and minimum and maximum values rather than a pass/fail?
- Can you provide HPHC characterization data for your nicotine ingredient as supplied, at the specifications relevant to our product format?
- What documentation covers your manufacturing partner's GMP status, certification history, and audit records?
- If FDA calls us mid-review with an ingredient question, what is your committed turnaround for supplying the supporting record?
A supplier that cannot answer these with specific documentation is a compliance risk in a review process that now moves quickly.
Frequently Asked Questions
Was FDA's nicotine pouch PMTA pilot canceled?
No. FDA closed the pilot to new entrants but did not shut it down. On May 7, 2026, CTP Acting Director Bret Koplow stated that "No additional products will be added to the nicotine pouch pilot" and that CTP "intends to incorporate lessons learned from the pilot into the review for all nicotine pouch PMTAs." The pilot continued producing decisions after that: on August 4, 2026, FDA authorized four more on! nicotine pouch products from Helix Innovations LLC through the pilot and credited it with faster resolution of issues, shorter applicant response times on deficiency letters, and more efficient scientific reviews. FDA has begun applying those efficiencies to other PMTAs.
Did the pilot lower the documentation standard for nicotine pouch PMTAs?
No. FDA's announcements describe process changes, not evidentiary relaxations. The pilot focused review on the most critical elements for the product category and introduced increased real-time communication between FDA and applicants so that missing information could be addressed sooner. The legal standard was unchanged: a product must still be shown to be appropriate for the protection of the public health under Section 910(c)(2) of the FD&C Act, with submissions governed by 21 CFR Part 1114. FDA did not announce any waiver permitting category-wide literature to substitute for product-specific evidence.
How many nicotine pouch products has FDA authorized?
FDA's authorized nicotine pouch list contained 32 products as of August 19, 2026, from two manufacturers: Swedish Match USA (20 ZYN products, authorized January 16, 2025) and Helix Innovations LLC (six on! PLUS products authorized in December 2025, plus on! products authorized through 2026). All other nicotine pouches on the US market lack marketing authorization. FDA maintains the current list at fda.gov/authorizednicotinepouches and updates it the day of an authorization.
Does my nicotine supplier need a Tobacco Product Master File (TPMF) on file with FDA?
A TPMF is not legally required, but it is strategically significant. A TPMF lets the supplier submit confidential ingredient and composition data directly to FDA. The manufacturer cross-references it in the PMTA without the supplier's proprietary data being disclosed to the applicant or the public. This protects supplier IP while giving the PMTA a stronger documentation foundation. Without a supplier TPMF, manufacturers must document ingredient details themselves or negotiate direct data sharing, typically with less precision and less IP protection for both parties.
The pilot is not the story. The process it proved out is, because FDA is extending that process to every nicotine pouch PMTA and, in its own words, has "begun implementing efficiencies learned from the pilot to the review of other PMTAs."
A faster review is only an advantage to applicants who can keep up with it. The companies that come out of this period with authorized products will be the ones whose documentation packages were audit-ready before FDA asked, because the window between the question and the answer is now measured in days. That readiness starts with the ingredient supply chain. NicAlliance supplies USP/EP grade nicotine with full documentation support for PMTA submissions, backed by a certified US-based manufacturing partner.